Vimarsana
Biggest News Aggregation in the World

Page 38 - Structural Heart News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Structural Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Structural Heart Today - Breaking & Trending Today

BayCare Receives Recognition for its Minimally Invasive Transcatheter Valve Procedures - Vimarsana News

BayCare Receives Recognition for its Minimally Invasive Transcatheter Valve Procedures

/PRNewswire/ -- The structural heart programs at BayCare's Morton Plant Hospital in Clearwater and St. Joseph's Hospital in Tampa recently received the...

Study supports Boston Scientific's Acurate neo2 aortic valve system - Vimarsana News

Study supports Boston Scientific's Acurate neo2 aortic valve system

New registry data demonstrates positive hemodynamic performance and clinical outcomes with the Boston Scientific Acurate neo2 TAVI system.

Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase - Vimarsana News

Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase

Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdownsDUBLIN, May 26, 2022 /PRNews...

Medtronic plc (MDT) CEO Geoff Martha on Q4 2022 Results - Earnings Call Transcript - Vimarsana News

Medtronic plc (MDT) CEO Geoff Martha on Q4 2022 Results - Earnings Call Transcript

Medtronic plc (NYSE:NYSE:MDT) Q4 2022 Earnings Conference Call May 26, 2022, 08:00 AM ET Company Participants Ryan Weispfenning - Head of IR Geoff Martha - CEO Karen Parkhill - CFO Brad...

Medtronic enrolls first patient in trial of Evolut TAVR system in patients with aortic stenosis - Vimarsana News

Medtronic enrolls first patient in trial of Evolut TAVR system in patients with aortic stenosis

Medtronic (NYSE:MDT) announced today that it enrolled the first patient in its Expand TAVR II pivotal trial.